NORD and Amgen Launch Major Rare Disease Learning Collaborative to Tackle Diagnostic Delays in Autoimmune Conditions

WASHINGTON, D.C., October 27, 2026 — In a significant move aimed at closing critical gaps in the healthcare landscape, the National Organization for Rare Disorders (NORD®) today announced a major partnership with Amgen to launch a specialized Learning Collaborative. Operating through NORD’s esteemed Rare Disease Centers of Excellence Network, this 14-month pilot initiative is financially supported by a strategic sponsorship investment from Amgen. The primary mission of the collaborative is to aggressively reduce the prolonged time it takes to secure an accurate diagnosis for rare diseases—a systemic challenge that continues to impact millions of patients globally and across the United States.

The newly established pilot will bring together five to eight participating institutions from the nationwide network to address persistent, complex obstacles in diagnosing and managing individuals living with rare autoimmune diseases. Initially, the collaborative will focus its intensive efforts on two specific conditions: IgG4-Related Disease (IgG4-RD) and Thyroid Eye Disease (TED). Both of these medical conditions are notorious for being exceptionally difficult to recognize in clinical settings, frequently requiring coordinated medical care across multiple specialized medical disciplines before a definitive diagnosis can be made and an effective treatment plan can be established.

Through the structure of this pilot program, experienced clinicians hailing from participating NORD Rare Disease Centers of Excellence will collaborate directly with affected patients, dedicated family caregivers, and disease-specific advocacy organizations. Together, these stakeholders will examine every step of the patient journey to pinpoint exactly where breakdowns occur in diagnosis, specialist referrals, critical treatment decisions, and ongoing care coordination. By drawing heavily on direct clinical experience, valuable patient insights, and structured, comprehensive reviews of existing care pathways, the collaborative will identify tangible opportunities for improvement and develop practical, real-world resources designed to aid clinicians on the front lines of medicine.

The overarching design of the initiative is built to generate two distinct categories of learning and impact. First, it will formulate disease-specific approaches aimed at dramatically improving early recognition and clinical care pathways specifically for IgG4-RD and TED. Second, it will harvest broader, macro-level insights concerning the root causes of diagnostic delays, the hurdles inherent in specialist referrals, and the complexities of multi-disciplinary care coordination. These broader lessons are intended to hold direct applicability for a wide array of other rare diseases that face remarkably similar operational and diagnostic hurdles. Participating medical centers will actively share their findings and continuously refine their approaches so that successful strategies can be efficiently adapted across other healthcare institutions nationwide.

Pam Gavin, President and Chief Executive Officer of NORD, emphasized the visionary nature of the network when addressing the announcement. When NORD originally established its flagship Rare Disease Centers of Excellence network, the core vision was to intentionally bring together the combined expertise, intellect, and physical resources of leading medical institutions to tackle systemic challenges that no single healthcare facility could possibly solve in isolation. Gavin noted that Amgen demonstrated a deep, authentic commitment to the rare disease community by recognizing the immense potential of this network and stepping forward with the necessary support to help turn that vision into concrete, actionable reality. By working collaboratively across institutions and working side-by-side with patients and clinical experts, the partnership opens a vital window of opportunity to address the precise challenges inherent in these two complex diseases while simultaneously forging scalable approaches that can eventually benefit countless other rare disease communities.

This newly launched Learning Collaborative also directly advances the overarching goals of SPAARK, which stands for Strengthening Partnerships to Advance Autoimmune Rare Disease Knowledge. SPAARK is an Amgen-led coalition that currently unites 10 distinct advocacy and professional organizations, including NORD itself, working collectively toward a bold shared objective: reducing the average time it takes to achieve a rare autoimmune disease diagnosis by an ambitious 50 percent by the year 2036.

The human toll of these diagnostic delays and the complexity of ongoing disease management was highlighted by Kat Provencher, Director of Patient Advocacy for the IgG4ward! Foundation. Speaking as both an advocate and a family caregiver to her husband, Andy, who lives with IgG4-related disease, Provencher shared firsthand insight into how deeply overwhelming it can be to successfully navigate a complex, poorly understood disease while desperately searching for the right medical answers and high-quality care. For families like hers and countless others across the country, Provencher noted, the grueling challenges do not magically evaporate the moment a diagnosis is finally handed down. Coordinating ongoing care across a fractured array of medical specialists and understanding the long-term path forward can prove to be just as difficult and emotionally taxing. What brings her profound hope regarding this new collaboration is the direct inclusion of patients and caregivers who will finally have an empowered voice in identifying precisely where the medical system falls short, thereby helping to shape practical solutions that will ultimately make the journey much easier for those who follow.

Echoing these sentiments from the corporate and clinical development perspective, Paul Burton, M.D., Ph.D., senior vice president and chief medical officer at Amgen, addressed the unacceptable status quo faced by so many patients. For an overwhelming number of individuals living with rare autoimmune diseases, the path leading from the onset of initial symptoms to a correct diagnosis and appropriate medical care is far too long and perpetually clouded by uncertainty. Burton stressed the foundational belief that patients inherently deserve answers much sooner than the current system typically allows. Through this strategic collaboration with NORD and the dedicated member organizations comprising the SPAARK alliance, diverse perspectives and top-tier expertise are being purposefully merged to aggressively dismantle the persistent barriers standing in the way of timely diagnoses, accelerate meaningful scientific and clinical progress, and ultimately help a greater number of people secure the specialized care and comprehensive support they desperately need.

The foundational infrastructure supporting this initiative was laid in 2021 when NORD officially established its Rare Disease Centers of Excellence network. Today, that expansive network encompasses 49 designated medical centers spanning more than 170 affiliated medical and research institutions. The primary purpose of the network is to seamlessly connect specialized clinical expertise with deep institutional resources to effectively bridge the historic gaps that have long plagued rare disease diagnosis, treatment, and ongoing patient care. The new Learning Collaborative builds directly upon that solid foundation by establishing a highly structured, collaborative opportunity for major medical institutions to learn continuously from one another and collectively develop pragmatic approaches to shared systemic challenges.

To maintain the utmost standards of integrity, NORD will maintain strict, independent scientific oversight over all activities conducted within the collaborative. All educational resources and clinical tools produced through the initiative will be carefully developed to support evidence-based, highly patient-centered care, strictly avoiding the promotion of any specific commercial medication, product, or proprietary treatment approach.

Founded in 1983, the National Organization for Rare Disorders (NORD®) operates as a leading independent, nonpartisan nonprofit organization dedicated entirely to improving the health, well-being, and overall quality of life for more than 30 million Americans currently living with rare diseases. Representing a vast coalition of over 350 disease-specific member patient organizations alongside its 49 designated Rare Disease Centers of Excellence and more than 170 affiliated institutions, NORD continues to advance comprehensive care, accelerate clinical research, expand educational opportunities, and champion powerful legislative advocacy on behalf of the entire rare disease population.

Siti Muinah

Penulis aktif di HypePress yang membagikan konten inspiratif, informasi terkini, dan gaya hidup untuk generasi muda.

Artikel Bermanfaat dan Menghibur Lainnya